Product Description
AL-78898A Inhibits Complement Deposition in a Primate Light Damage Model (Sourced from: https://iovs.arvojournals.org/article.aspx?articleid=2359062)
Mechanisms of Action: C3 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Alcon
Company Location: Europe
Company Founding Year: 1945
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Macular Degeneration|Geographic Atrophy|Wet Macular Degeneration
Phase 1: Wet Macular Degeneration
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00473928 |
ASaP | P1 |
Completed |
Wet Macular Degeneration |
2010-02-01 |
2019-03-21 |
||
NCT01603043 |
C-12-020 | P2 |
Terminated |
Geographic Atrophy|Macular Degeneration |
2012-11-01 |
2019-03-19 |
Treatments |
|
NCT01157065 |
RACE | P2 |
Completed |
Wet Macular Degeneration |
2012-04-01 |
2019-03-19 |